Summary: Enveric Biosciences announced that its EB-002 psilocin drug candidate has gained expanded protection under US Patent No 11,945,778, covering methods of treating brain neurological disorders, including sleep disorders. This patent joins two others, enhancing the intellectual property landscape for EB-002, which is developed for neuropsychiatric disorders. CEO Joseph Tucker highlights the importance of comprehensive patent portfolios in accelerating clinical development and bringing new drugs to patients swiftly.
Key Takeaways:
- Expanded Patent Coverage: Enveric Biosciences’ EB-002 drug candidate now has expanded patent protection under US Patent No 11,945,778, which includes methods of treating a range of brain neurological disorders such as sleep disorders, depression, substance-related disorders, and headaches.
- Intellectual Property Portfolio: EB-002 is protected under three US patents that cover its compositions, pharmaceutical formulations, methods of making the molecules, and methods of treating various brain neurological disorders.
- Strategic Advancement and Risk Mitigation: According to CEO Joseph Tucker, the patent coverage helps to derisk and accelerate the clinical development of EB-002.
Enveric Biosciences, a biotechnology company developing novel neuroplastogens for the treatment of neuropsychiatric disorders, announced the expansion of protection for potential clinical indications for its EB-002 drug candidate through the issuance of Patent No 11,945,778 by the United States Patent and Trademark Office.
The US patent issuance increases the company’s intellectual property protection of EB-002 by adding methods of treatment that claim a broad field of brain neurological disorders. The methods of treatment intend to apply to neurological disorders such as sleep disorders, depression, substance-related disorders, and headaches.
EB-002 is Enveric’s next-generation psilocin prodrug being developed for neuropsychiatric disorders, initially anxiety. EB-002 now has additional patent protection supporting the enhanced potential to expand into additional neurological conditions and serve a broad range of patient populations.
“EB-002, the lead compound that emerged from Enveric’s EVM201 screening program, now enjoys US patent coverage under three issued patents that claim: compositions and pharmaceutical formulations of EB-002 and closely related similar compounds (US 11,707,447), methods of making the molecules (US 11,845,726), and now methods of treating a broad range of brain neurological disorders using EB-002 and related compounds (US 11,945,778),” says Joseph Tucker, PhD, CEO of Enveric, in a release.
He adds, “Enveric believes that deploying comprehensive patent portfolios to protect lead drug development candidates helps to derisk and accelerate clinical development, furthering the company’s efforts to rapidly bring this new drug to patients.”
Leave a Reply